Neurogen Corporation Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson's Disease
BRANFORD, Conn.--(BUSINESS WIRE)--Neurogen Corporation (Nasdaq: NRGN - News) today announced positive top-line results from two Phase 2 clinical trials in restless legs syndrome (RLS) and Parkinson’s disease with the Company’s dopamine partial agonist, aplindore. These studies were the first in which aplindore has been evaluated in RLS and Parkinson’s disease.